AbbVie (ABBV)
(Delayed Data from NYSE)
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$195.45 USD
-1.37 (-0.70%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $194.88 -0.57 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
ImmunoGen (IMGN) Q1 Earnings Top, Pivotal Studies Delayed
by Zacks Equity Research
ImmunoGen (IMGN) reports narrower-than-expected loss but misses revenue estimates. Meanwhile, data readouts from pivotal studies on lead candidate get delayed due to COVID-19. Stock down.
Ironwood's (IRWD) Q1 Earnings Beat, 2021 Guidance Muted
by Zacks Equity Research
Ironwood (IRWD) witnesses strong demand for Linzess in the first quarter. However, outlook for 2021 misses market expectations. Stock down.
Reata's (RETA) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Reata (RETA) reports mixed first-quarter results wherein earnings beat estimates but sales miss the same. Stock rises.
Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABBV) Outperforming Other Medical Stocks This Year?
AbbVie (ABBV) Stock Moves -0.61%: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $113.98 in the latest trading session, marking a -0.61% move from the prior day.
3 Big Drugmaker Stocks to Watch Out For Amid Pandemic Woes
by Kinjel Shah
Most Large Cap Pharmaceuticals industry players' Q1 results have been disappointing. Launch of COVID-19 vaccines and medicines is playing a crucial role in driving the industry. PFE, JNJ and AZN may prove to be good additions to your portfolio.
AbbVie (ABBV) Beats on Q1 Earnings, Raises 2021 Guidance
by Zacks Equity Research
AbbVie (ABBV) beats on first-quarter 2021 earnings and revenues. Shares up in pre-market trading.
AbbVie (ABBV) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 6.50% and 0.51%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Big Cap Earnings Superstars
by Tracey Ryniec
It's not easy for companies to beat on earnings nearly every quarter for years but these five are doing it.
Healthcare ETFs on Radar As Q1 Earnings Unfold
by Sweta Killa
Further price movement of the healthcare ETFs depend on earnings releases from some big names like Pfizer (PFE), Merck (MRK), Thermo Fisher (TMO), AbbVie (ABBV), and Gilead Sciences (GILD) that dominate returns.
This is Why AbbVie (ABBV) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.
Strong New Drugs Sales to Aid AbbVie's (ABBV) Q1 Earnings
by Zacks Equity Research
AbbVie (ABBV) is expected to have witnessed a recovery in demand trends for new drugs amid improving global economies. However, resurgence of COVID-19 cases is likely to have hurt sales of physician-administered drugs.
Amgen (AMGN) Q1 Earnings, Sales Miss on Low Prices, Stock Down
by Zacks Equity Research
Amgen (AMGN) misses Q1 estimates for both earnings and sales. Shares decline in after-hours trading.
Editas (EDIT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.
AbbVie (ABBV) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, AbbVie (ABBV) closed at $111.39, marking a +0.01% move from the previous day.
What's in the Cards for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for Humira in the United States to boost AbbVie's (ABBV) first-quarter sales.
J&J (JNJ) Q1 Earnings Top, COVID-19 Vaccine Brings $100M Sales
by Zacks Equity Research
J&J (JNJ) beats first-quarter 2021 estimates for both earnings and sales. It boosts quarterly dividend by 5%.
AbbVie (ABBV) Gains As Market Dips: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $108.61 in the latest trading session, marking a +0.65% move from the prior day.
Anthem (ANTM) to Report Q1 Earnings: What's in its Store?
by Zacks Equity Research
Anthem's (ANTM) first-quarter earnings to reflect better revenues and higher membership.
Will Solid Pharma Unit Performance Drive J&J (JNJ) Q1 Earnings?
by Zacks Equity Research
In J&J's (JNJ) Pharma segment, its oncology drugs, Imbruvica and Darzalex as well as psoriasis treatment drug, Stelara, are likely to have driven sales growth.
Screening for Triple Threat Stocks: Value, Growth and Dividends
by Tracey Ryniec
Is it possible for investors to find cheap stocks that have double digit growth and that also pay a great dividend yield?
Will J&J (JNJ) Kickstart Pharma Q1 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market while moderate procedural disruption might have hurt the Medical Devices segment in the first quarter.
Top Research Reports for Home Depot, Toyota & IBM
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot (HD), Toyota Motor (TM), and International Business Machines (IBM).
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
AbbVie (ABBV) closed at $108.22 in the latest trading session, marking a -0.03% move from the prior day.
What's in Store for Edwards Lifesciences (EW) in Q1 Earnings?
by Zacks Equity Research
Continued strength in the adoption of the TruWave disposable pressure monitoring devices and INSPIRIS RESILIA aortic valve are likely to have driven Edwards Lifesciences' (EW) Q1 revenues.